New oral drug aims to cut dangerous COPD exacerbations
Disease control
Recruiting now
This Phase 2 study tests whether a once-daily oral tablet called EXPD-101 can reduce the number of moderate to severe COPD flare-ups in people with chronic bronchitis. Participants must have had at least two moderate or one severe exacerbation in the past year. The trial compares…
Phase: PHASE2 • Sponsor: Expedition Therapeutics, Inc • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC